Literature DB >> 20940108

Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients.

Gerd Döring1.   

Abstract

In patients with cystic fibrosis (CF) prevention of lung infections with Pseudomonas aeruginosa is of major importance. Principles to achieve this goal include vaccination, immediate use of antibiotics in patients newly colonized with the pathogen, and hygienic measures. The purpose of this review is to discuss recent developments in this context.
Copyright © 2010. Published by Elsevier GmbH.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20940108     DOI： 10.1016/j.ijmm.2010.08.010

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN： 1438-4221            Impact factor:   3.473


  10 in total

1.  Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.

Authors:  Shalini Yapa; Jian Li; Kashyap Patel; John W Wilson; Michael J Dooley; Johnson George; Denise Clark; Susan Poole; Elyssa Williams; Christopher J H Porter; Roger L Nation; Michelle P McIntosh
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

2.  Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.

Authors:  Sally Palser; Sherie Smith; Edward F Nash; Arnav Agarwal; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17

Review 3.  Virulence Factors of Pseudomonas Aeruginosa and Antivirulence Strategies to Combat Its Drug Resistance.

Authors:  Chongbing Liao; Xin Huang; Qingxia Wang; Dan Yao; Wuyuan Lu
Journal:  Front Cell Infect Microbiol       Date:  2022-07-06       Impact factor: 6.073

4.  Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Authors:  Ryka Moore; Jennelle M Kyd; Rosemary Carzino; Davide Armstrong; Keith Grimwood; Diana C Otczyk; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

5.  Anti-inflammatory effects of tobramycin and a copper-tobramycin complex with superoxide dismutase-like activity.

Authors:  M Gziut; H J MacGregor; T G Nevell; T Mason; D Laight; J K Shute
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 6.  Emerging therapies against infections with Pseudomonas aeruginosa.

Authors:  Burkhard Tümmler
Journal:  F1000Res       Date:  2019-08-07

Review 7.  Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Authors:  Maite Sainz-Mejías; Irene Jurado-Martín; Siobhán McClean
Journal:  Cells       Date:  2020-12-05       Impact factor: 6.600

Review 8.  Pseudomonas aeruginosa: Recent Advances in Vaccine Development.

Authors:  Matthew Killough; Aoife Maria Rodgers; Rebecca Jo Ingram
Journal:  Vaccines (Basel)       Date:  2022-07-08

9.  Successful implementation of infection control strategies prevents P. aeruginosa transmission among cystic fibrosis patients inside the hospital.

Authors:  Benedikt Matt; Dieter Mitteregger; Sabine Renner; Elisabeth Presterl; Ojan Assadian; Magda Diab-Elschahawi
Journal:  GMS Hyg Infect Control       Date:  2014-09-30

10.  The LysR-Type Transcriptional Regulator BsrA (PA2121) Controls Vital Metabolic Pathways in Pseudomonas aeruginosa.

Authors:  Magdalena Modrzejewska; Adam Kawalek; Aneta Agnieszka Bartosik
Journal:  mSystems       Date:  2021-07-13       Impact factor: 6.496
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.